Adding Ibrance to fulvestrant does not benefit patients with breast cancer refractory to CDK4/6 inhibitors
NEW YORK – For patients whose HER2-negative and hormone receptor-positive metastatic breast cancers progress after treatment with combination CDK4/6 inhibitors and hormone therapy, there is no additional benefit to continuing treatment with Pfizer Ibrance’s CDK4/6 inhibitor (palbociclib) plus another hormone therapy as the next line of treatment, suggest phase II study results presented at the …